Fait Optics signs on as distribution lab for Avulux Migraine & Light Sensitivity Lens, making innovative new lens available to more eye care providers in the U.S.
MIAMI – February 9, 2023 – Avulux announced that the world’s only clinically proven lens that blocks the harmful light wavelengths linked to migraine attacks is now available to eye care providers (ECPs) in the U.S. through Fait Optics, one of the nation’s leading vision care distributors.
“The new, patented technology behind the Avulux Migraine & Light Sensitivity Lens blocks blue, amber and red light while letting in soothing green light,” said Dr. Charles Posternack, President and Co-Founder of Avulux. “We are pleased to partner with Fait Optics to make this lens available through more eye care providers across the United States.”
Fait Optics is now an Authorized Avulux Lab. Eye care providers who partner with Avulux Authorized Labs have access to the company’s efficient supply chain, bulk/wholesale discounts and bonuses, as well as a robust offering of informational and promotional materials to support ECPs in making Avulux lenses available in their practices. Avulux and its Authorized Labs stand behind the lenses with warranties and guarantees.
“We chose to become an Authorized Avulux Lab because we believe the Avulux Migraine & Light Sensitivity Lens is a critical tool for eye care providers looking to help patients who are experiencing migraine and light sensitivity,” said Chad Moder, Vice President, Sales, Fait Optics.
Avulux lenses enable eye care providers to act as a front-line defense in helping people with migraine and light sensitivity to manage the impact of light on their daily lives. They also give eye care providers the opportunity to differentiate their practice and drive revenue growth by providing an innovative new solution.
For more information about Fait Optics, visit faitships.com.
For more information about Avulux, visit www.avulux.com.